Your browser doesn't support javascript.
loading
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Ruiz de Porras, Vicenç; Wang, Xieng C; Palomero, Luis; Marin-Aguilera, Mercedes; Solé-Blanch, Carme; Indacochea, Alberto; Jimenez, Natalia; Bystrup, Sara; Bakht, Martin; Conteduca, Vincenza; Piulats, Josep M; Buisan, Oscar; Suarez, José F; Pardo, Juan Carlos; Castro, Elena; Olmos, David; Beltran, Himisha; Mellado, Begoña; Martinez-Balibrea, Eva; Font, Albert; Aytes, Alvaro.
Afiliación
  • Ruiz de Porras V; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain.
  • Wang XC; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain.
  • Palomero L; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain.
  • Marin-Aguilera M; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Solé-Blanch C; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain.
  • Indacochea A; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Jimenez N; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Bystrup S; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via de L'Hospitalet, Barcelona, Spain.
  • Bakht M; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Conteduca V; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.
  • Piulats JM; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barce
  • Buisan O; Department of Urology, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Suarez JF; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Department of Urology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain.
  • Pardo JC; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain.
  • Castro E; Genitourinary Cancer Translational Research Group, The Institute of Biomedical Research in Málaga, Málaga, Spain; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.
  • Olmos D; Genitourinary Cancer Translational Research Group, The Institute of Biomedical Research in Málaga, Málaga, Spain; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.
  • Beltran H; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Mellado B; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.
  • Martinez-Balibrea E; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via de L'Hospitalet, Barcelona, Spain.
  • Font A; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain. Electronic address: afont@iconcologia.net.
  • Aytes A; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via d
Eur Urol ; 79(6): 722-733, 2021 06.
Article en En | MEDLINE | ID: mdl-33153817
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hidrocarburos Aromáticos con Puentes / Taxoides / Neoplasias de la Próstata Resistentes a la Castración / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Eur Urol Año: 2021 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hidrocarburos Aromáticos con Puentes / Taxoides / Neoplasias de la Próstata Resistentes a la Castración / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Eur Urol Año: 2021 Tipo del documento: Article País de afiliación: España